Anti-LIRA4/ LILRA4/ CD85g monoclonal antibody

Anti-LIRA4/ LILRA4/ CD85g antibody for FACS & in-vivo assay

Target products collectionGo to LILRA4/LILRA4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0733-Ab-1/ GM-Tg-hg-MP0733-Ab-2Anti-Human LILRA4 monoclonal antibodyHuman
GM-Tg-rg-MP0733-Ab-1/ GM-Tg-rg-MP0733-Ab-2Anti-Rat LILRA4 monoclonal antibodyRat
GM-Tg-mg-MP0733-Ab-1/ GM-Tg-mg-MP0733-Ab-2Anti-Mouse LILRA4 monoclonal antibodyMouse
GM-Tg-cynog-MP0733-Ab-1/ GM-Tg-cynog-MP0733-Ab-2Anti-Cynomolgus/ Rhesus macaque LILRA4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0733-Ab-1/ GM-Tg-felg-MP0733-Ab-2Anti-Feline LILRA4 monoclonal antibodyFeline
GM-Tg-cang-MP0733-Ab-1/ GM-Tg-cang-MP0733-Ab-2Anti-Canine LILRA4 monoclonal antibodyCanine
GM-Tg-bovg-MP0733-Ab-1/ GM-Tg-bovg-MP0733-Ab-2Anti-Bovine LILRA4 monoclonal antibodyBovine
GM-Tg-equg-MP0733-Ab-1/ GM-Tg-equg-MP0733-Ab-2Anti-Equine LILRA4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0733-Ab-1/ GM-Tg-hg-MP0733-Ab-2; GM-Tg-rg-MP0733-Ab-1/ GM-Tg-rg-MP0733-Ab-2;
GM-Tg-mg-MP0733-Ab-1/ GM-Tg-mg-MP0733-Ab-2; GM-Tg-cynog-MP0733-Ab-1/ GM-Tg-cynog-MP0733-Ab-2;
GM-Tg-felg-MP0733-Ab-1/ GM-Tg-felg-MP0733-Ab-2; GM-Tg-cang-MP0733-Ab-1/ GM-Tg-cang-MP0733-Ab-2;
GM-Tg-bovg-MP0733-Ab-1/ GM-Tg-bovg-MP0733-Ab-2; GM-Tg-equg-MP0733-Ab-1/ GM-Tg-equg-MP0733-Ab-2
Products NameAnti-LILRA4 monoclonal antibody
Formatmab
Target NameLILRA4
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LILRA4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-135Pre-Made Daxdilimab biosimilar, Whole mAb, Anti-LILRA4/ILT7 Antibody: Anti-CD85g therapeutic antibody
    Target AntigenProducts DevelopingMulti-species LIRA4/ LILRA4/ CD85g VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0733
    Target NameLILRA4
    Gene ID23547,695197
    Gene Symbol and SynonymsCD85g,ILT7,LILRA4
    Uniprot AccessionP59901
    Uniprot Entry NameLIRA4_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, INN Index
    DiseaseN/A
    Gene EnsemblENSG00000239961
    Target ClassificationN/A

    The target: LILRA4, gene name: LILRA4, also named as CD85g, ILT7. This gene encodes an immunoglobulin-like cell surface protein that is expressed predominantly on plasmacytoid dendritic cells (PDCs) and modulates the function of these cells in the immune response. Expression of this gene is downregulated by interleukin 3 (IL3). This gene is one of a cluster of highly related genes located at chromosomal region 19q13.4. [provided by RefSeq, Jan 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.